Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Emergent Evaluation and Management Of Pelvic Inflammatory Disease

By ACEP Now | on January 1, 2010 | 0 Comment
CME CME Now
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

In well-appearing patients, an alternate therapy includes levofloxacin (500 mg orally daily for 14 days), but these patients require close follow-up to determine if symptoms are improving, as well as a test of cure at the conclusion of therapy.

You Might Also Like
  • Critical Issues in the Initial Evaluation and Management of Patients Presenting to the Emergency Department in Early Pregnancy
  • Evaluation and Management of Suspected Appendicitis
  • Critical Decisions: Pediatric Sickle Cell Disease – Part Two
Explore This Issue
ACEP News: Vol 29 – No 01 – January 2010

Inpatient treatment regimens closely follow outpatient recommendations. The CDC recommends one of these two regimens:

  • Cefoxitin (2 g IV every 6 hours) or cefotetan (2 g IV every 12 hours) plus doxycycline (100 mg IV or p.o. every 12 hours).
  • Clindamycin (900 mg IV every 8 hours) plus gentamicin loading dose (2 mg/kg) followed by a maintenance dose (1.5 mg/kg every 8 hours). Either regimen results in a clinical cure in more than 90% of cases.18

Many patients initially admitted for parenteral therapy can be transitioned to oral therapy to complete the course; this transition typically occurs 24 hours after sustained clinical improvement.15

the cdc recommends that health care providers maintain a low threshold for diagnosis and empiric treatment of presumed PID.

Complications

Even with prompt diagnosis and appropriate treatment of PID, complications are frequent, resulting from the scarring and adhesion formation that develop while the infected organs heal.

Immediate complications include tubo-ovarian abscess and Fitz-Hugh-Curtis syndrome, while the longterm complications include chronic pelvic pain, infertility, and ectopic pregnancy.

Tubo-ovarian abscess (TOA) is one of the most immediate and life-threatening complications of PID. Up to one-third of patients may experience this complication, which occurs when purulent material gains access to the ovary via the fallopian tube.

TOA is a polymicrobial infection that leads to worsening abdominal pain with unilateral adnexal tenderness and fever. Patients with TOA should be hospitalized until they begin to improve, as abscess rupture is a surgical emergency and can rapidly lead to sepsis, shock, and death.

Fitz-Hugh-Curtis syndrome refers to a perihepatitis resulting from peritoneal dissemination of PID. Inflammation and swelling of the liver capsule lead to pleuritic right upper quadrant pain.

Fitz-Hugh-Curtis syndrome affects up to a quarter of women diagnosed with PID, and in chronic cases, the formation of adhesions can lead to persistent pain.20

Chronic pelvic pain, defined as infraumbilical pain of at least 6 months’ duration that is severe enough to cause functional disability, is one of the causes of long-term morbidity following a case of PID.

Chronic pelvic pain occurs in up to one-third of women who are diagnosed with PID, and there is currently no cure. Recurrent episodes of PID are the strongest predictor in the development of chronic pelvic pain.21

Pages: 1 2 3 4 5 6 7 | Single Page

Topics: Abdominal and GastrointestinalAntibioticClinical ExamClinical GuidelineCMEDiagnosisEducationEmergency MedicineEmergency PhysicianImaging and UltrasoundPainPractice ManagementProcedures and SkillsTechnologyUrogenital

Related

  • Florida Emergency Department Adds Medication-Dispensing Kiosk

    November 7, 2025 - 1 Comment
  • Q&A with ACEP President L. Anthony Cirillo

    November 5, 2025 - 0 Comment
  • FACEPs in the Crowd: Dr. John Ludlow

    November 5, 2025 - 0 Comment

Current Issue

ACEP Now: November 2025

Download PDF

Read More

About the Author

ACEP Now

View this author's posts »

No Responses to “Emergent Evaluation and Management Of Pelvic Inflammatory Disease”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603